



Living Cell Technologies Ltd

COMPANY ANNOUNCEMENT

Living Cell Technologies to Present Positive Preliminary Clinical Results at the International Diabetes Federation Congress

February 13, 2008 – Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTC: LVCLY.PK) today announced that the Company's positive preliminary clinical results will be presented at the upcoming 7th International Diabetes Federation (IDF) Western Pacific Region Congress.

LCT's Medical Director, Professor Bob Elliott, has been invited to update a group of international diabetes experts on the successful implant of DiabeCell[®], the encapsulated porcine, insulin producing cells for the treatment of type 1 diabetes. The LCT presentation is scheduled for March 31, 2008 in Wellington, New Zealand.

LCT's lead product, DiabeCell[®] is presently in Phase I/IIa clinical trials. As previously reported on October 9 and October 22, 2007, the early results of the Russian clinical trial exceeded expectations in the first group of patients, where they were given the lowest dose of DiabeCell[®]. The clinical trial commenced in June 2007 and the first patient has now completed 6 months follow-up, maintaining clinical benefit with no evidence of immune rejection. The prolonged survival and effect of LCT's DiabeCell[®] have been attained without the need for immunosuppressive or anti-rejection drugs.

Professor Elliott is to summarize the available follow-up data on all patients implanted with DiabeCell[®] at the upcoming IDF congress.

LCT's Chief Executive Officer, Dr Paul Tan stated, "This international forum will provide an excellent opportunity to report the positive results from the ongoing trial, including the added benefits of a re-implant with a second dose."

Dr. Paul Tan CEO Mob: 0402 716 984 (AUS) 021 608 784 (NZ) Tel: +64 9 270 7941 ptan@lctglobal.com	Dr. Bob Elliott Medical Director Mob: +64 27 292 4177 Tel:+64 9 276 2690 relliott@lctglobal.com	Investor and Media Relations Rebecca Wilson Buchan Consulting P:+612 9237 2800 M: +61 (0)417 382 391 rwilson@bcg.com.au	Investor and Media Relations (U.S.) Leslie Wolf Creutzfeldt The Global Consulting Group Tel: +1-646-284-9472 lwolf-creutzfeldt@hfgcg.com
---	---	---	---

About Living Cell Technologies: www.lctglobal.com

Living Cell is developing cell-based products to treat life threatening human diseases. The Company owns a biocertified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. For patients with Type 1 diabetes, the Company transplants microencapsulated islet cells so that near-normal blood glucose levels may be achieved without the need for administration of insulin or at significantly reduced levels. The company entered clinical trials for its diabetes product in 2007. For the treatment of Huntington's disease and other neurological disorders, the company transplants microencapsulated choroid plexus cells that deliver beneficial proteins and neurotrophic factors to the brain. Living Cell's technology enables healthy living cells to be injected into patients to replace or repair damaged tissue without requiring the use of immunosuppressive drugs to prevent rejection. Living Cell also

offers medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.

LCT Disclaimer

This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information as of February 13, 2008, and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.